Combinatorial immunotherapy and nanoparticle mediated hyperthermia

Citation:

A. J. Moy and Tunnell, J. W., “Combinatorial immunotherapy and nanoparticle mediated hyperthermia,” Advanced Drug Delivery Reviews, vol. 114, pp. 175 - 183, 2017.

Abstract:

Immune checkpoint therapy has become the first widely adopted immunotherapy for patients with late stage malignant melanoma, with potential for a wide range of cancers. While some patients can experience long term disease remission, this is limited only to a subset of patients and tumor types. The path forward to expand this therapy to more patients and tumor types is currently thought to be combinatorial treatments, the combination of immunotherapy with other treatments. In this review, the combinatorial approach of immune checkpoint therapy combined with nanoparticle-assisted localized hyperthermia is discussed, starting with an overview of the different nanoparticle hyperthermia approaches in development, an overview of the state of immune checkpoint therapy, recent reports of immune checkpoint therapy and nanoparticle-assisted hyperthermia in a combinatorial approach, and finally a discussion of future research topics and areas to be explored in this new combinatorial approach to cancer treatment.

Notes:

Immuno-engineering: The Next Frontier in Therapeutics Delivery

Website